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Objective: To characterize the antitoxoplasma activity of clindamycin in a murine model of acute toxoplasmosis. 
Methods: Rates of survival and mean survival times of Swiss Webster mice infected intraperitoneally with lo6-lo2 
tachyzoites of the RH strain of Toxoplasma gondii treated with clindamycin or sulfamethoxazole (positive control) or 
untreated (negative control) were compared. Survivors were submitted to examination of untreated brain tissue pre- 
parations, intraperitoneal and peroral .subinoculations of brain tissue homogenates into fresh mice, and to patho- 
histology, including immunohistochemistry, of brain and lungs. 
Results: The effect of clindamycin treatment (400 mg/kg/day) on infected Swiss Webster mice was inoculum size 
dependent, ranging from no survivals in animals infected with lo6 parasites, to 100% survivals with an inoculum of lo2. 
Treatment initiated 24 h before and at time of infection prolonged mean survival times comparably to sulfamethoxazole, 
and significantly when compared to untreated controls. In contrast, treatment initiated 48 h postinfection with an 
inoculum of lo6 did not postpone death. In the clindamycin-treated survivors, there was no biological or histologic 
evidence for the persistence of toxoplasma. 
Conclusions: The results obtained show that at an appropriate parasite dose/drug dose ratio, clindamycin is strongly 
toxoplasmacidal in a murine model of acute toxoplasmosis. 
Key words: Toxoplasma gondii, murine model, clindarnycin 
INTRODUCTION 
Toxoplasmic encephalitis (TE) has emerged as one of 
the major causes of death and the leading cause of focal 
cerebral lesions in AIDS patients [l]. It is generally 
considered to develop as a consequence of reactivation 
of latent (chronic) infection, i.e. cyst rupture and 
tachyzoite proliferation. A TE episode will eventually 
advance to death unless promptly treated. As at present 
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there is no drug regimen efficacious against toxoplasma 
cysts, treatment of TE must be followed by lifelong 
maintenance therapy. 
Standard therapy comprises a combination of 
pyrimethamine and sulfonamide drugs. However, 60% 
of the patients receiving this regimen experienced 
toxicity, the severity of which led to treatment discon- 
tinuation in up to 45% of patients [2]. Newer drugs 
with anti-tachyzoite activity, such as clarithromycin [3] 
and roxithromycin [4], and others with presumed anti- 
bradyzoite activity, such as atovaquone [5] and azi- 
thromycin [6], are still being evaluated. On  the other 
hand, the long-known lincosamide antibiotic clinda- 
mycin is often included in treatment protocols. Its 
efficacy in the treatment of toxoplasmic chorioretinitis 
has been established both experimentally [7] and 
clinically [8,9]. In AIDS patients, pyrimethamine 
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combined with clindamycin was shown to be an 
acceptable alternative to the pyrimethamine-sulfa- 
diazine combination in terms of efficacy, with lower 
toxicity [10-12]. 
Contradictory reports on the antitoxoplasma 
activity of clindamycin in animal models [13-161 were 
followed by recent observations of strong but delayed 
in vitro parasiticidal capacity [17,18]. Ths provided 
the impetus to evaluate and firther characterize the 
antitoxoplasma activity of clindamycin in an in vivo 
experimental model. 
MATERIALS AND METHODS 
Mice 
Female Swiss Webster mice (5-6 weeks old, weighing 
18-20g at the beginning of experiments), purchased 
fiom the Animal Research Facdity of the Medical 
Military Academy (Belgrade, Yugoslavia), were used in 
all experiments. 
Parasites 
Tachyzoites of the virulent RH strain of Toxoplarma 
gondii maintained through serial intraperitoneal passages 
were used. The parasite numbers were adjusted to 
2 x 106/mL with saline. Such suspensions were serially 
ten-fold diluted up to 2 X 102/mL. For experimental 
procedures, 0.5-mL aliquots of different dilutions, 
depending on the particular experiment, were inocu- 
lated intraperitoneally into mice. 
Drugs 
Clindamycin 
Powdered clindamycin hydrochloride (lot 353YS, 
Upjohn Co., supplied by Yusapharm, Belgrade) was 
administered at a dose of 400 mg/kg/day. Based on the 
observation that mice consume 4 g of food daily [19], 
the desired dose was obtained by adding 2mg of 
clindamycin per 1 g of ground mouse food. 
Sulfamethoxazole 
Sulfamethoxazole (lot SR723, ICN Galenika, Belgrade) 
was used as a representative sulfonamide drug of good 
efficacy that is well tolerated by mice [3]. A concen- 
tration of 700 mg/L in drinking water offered ad libitum 
provided a dose of 375 mg/kg/day. 
Neither drug administered for 3 weeks at the above 
doses had an effect on the survival of normal mice 
during an observation period of at least 3 months, and 
no clinically significant toxicity was observed. 
Experimental design 
Mice injected intraperitoneally with 106-102 parasites 
were divided into three treatment groups: group I, 
clindamycin-treated animals; group 11, sul€ameth- 
oxazole-treated animals (positive control); and group 
111, untreated animals (negative control). Treatment 
groups were further divided into subgroups according 
to whether the drug was introduced 24 h prior to 
infection, at the time of infection, or 48 h post- 
infection. Each treatment subgroup consisted of 6-12 
animals. Both drugs were applied for 3 weeks. The 
observation period following the discontinuation of 
treatment was 5 weeks. Based on the fact that murine 
infection with RH strain parasites is invariably lethal, 
the parameters for the evaluation of drug efficacy were 
survival rates and length of survival. Mouse survival was 
monitored daily. The experiments were performed two 
to five times each, and the data shown represent their 
cumulative results. 
To determine the outcome of the infection in 
clindamycin-treated anunals, groups of two arbitrarily 
chosen survivors infected with lo2 parasites were each 
lulled 3, 4, 6 and 8 weeks postinfection and the lungs 
and brains removed. Exact halves of all brains were 
homogenized and subinoculated into two fiesh mice 
per brain sample. While the RH strain is generally 
considered non-cystogenic for rodents, cyst develop- 
ment may occur following early treatment [20,21]. 
Therefore, in addition to intraperitoneal subinocu- 
lation for the detection of (pepsin-sensitive) tachy- 
zoites, the intraesophageal route was used to determine 
the presence of (pepsin-resistant) cysts. Survival was 
monitored over a period of 4 weeks. In addition, cysts 
were microscopically searched for in untreated pre- 
parations of the homogenized brain tissue &om mice 
lulled 6 weeks postinfection. 
Pathohistology 
Five-micrometer sections of formalin-fured, paraffin- 
embedded brains and lungs of experimental and control 
mice were hematoxylin-eosin stained for visualization 
of the pathologic processes involved. Detection of 
cysts was attempted by the periodic acid-ScM (PAS) 
reaction (for cyst contents), the Grocott moacat ion 
of the methenamine silver technique (for the cyst wall), 
and by imrnunoperoxidase staining. The peroxidase- 
antiperoxidase complex (PAP) technique [22] (PAP 
complex purchased fiom Dakopatts, Germany) was 
performed using a rabbit polyclonal antitoxoplasma 
serum (kindly provided by Dr Jean Francois 
Dubremetz) diluted 1 : 100 as the primary antibody. 
Statistics 
The correlation between survival and inoculum size 
was analyzed by multiple regression. Differences in the 
rates of survival were analyzed by the Kaplan-Meier 
product limit method. Differences in the survival times 
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between experimental and control mice were evaluated 
by one-way analysis of variance (ANOVA). The level 
of statistical significance was considered to be 0.05. 
RESULTS 
The results of clindamycin treatment initiated at the 
time of infection with a range of doses &om lo6 to 10’ 
parasites are presented in Figure 1. SuMval of mice 
treated with clindamycin was inoculum size dependent 
(y=3.01+0.86~, ~ 0 . 8 6 2 ,  df=95, p<O.OOOl),  ranging 
ffom zero (0%) in the group infected with lo6, to 100% 
in the group infected with 10’ (Figure 1A). With the 
exception of the lo6 inoculum size, the survival rates 
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Figure 1 Effect of clindamycin treatment as compared to no treatment in mice intraperitoneally infected with a 106-102 
dose range of RH T gondii tachyzoites. (A) SuMval rates. 0 Zclindamycin-treated mice; 
survival. Results expressed as mean survival time f SD. 0 =clindamycin-treated mice; x =untreated mice. *p<0.02, 
=untreated mice. @) Length of 
**p<O.O001. 
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of clindamycin-treated animals were si@icantly higher 
than those of untreated controls. In addition, as shown 
in Figure lB, mean survival times of clindamycin- 
treated animals infected with any parasite dose were 
significantly higher as compared to their respective 
controls. 
Since the above experiment clearly showed lo6 and 
102 to be the inoculum sizes which elicited extreme 
responses to treatment, further experiments were 
restricted to the use of these. 
To assess whether the therapeutic efficacy of 
clindamycin depends on the time of drug introduction, 
treatment was initiated 24 h prior to infection, at the 
time of infection, and 48 h postinfection. Clindamycin 
treatment in animals infected with lo6 parasites as 
compared to both sulfamethoxasole-treated animals 
and untreated controls showed no protective effects 
in terms of survival (Figure 2) .  On the other hand, 
sulfamethoxazole treatment initiated prior to and at  
the time of infection resulted in survival rates of 
44.4% (p<O.OOOl) and 55.6% (p<O.OOOl), respectively. 
Survival times of mice that succumbed to infection 
were sigdicantly higher (p<O.OOOl) than those of 
animals treated with clindamycin. Treatment by either 
drug initiated 48 h postinfection, however, had no 
effect as judged by either parameter, as compared to the 
negative control group (p>0.05). 
Figure 3 presents the results of the efficacy of 
treatment of mice infected with 10' parasites. Clinda- 
mycin treatment initiated at any time point sigdicantly 
prevented mortality when compared to untreated 
controls. The mouse survival rates in the groups treated 
24 h prior to and at the time of infection amounted 
to 100% (p<O.OOOl) and 83-100% (depending on 
particular experiment) (p<O.OOOl), respectively, whde 
in the group treated 48 h postinfection survival was 
58.3% (p<O.OOOl). The mean survival times were 
also significantly higher than in untreated animals 
(p<O.OOOl). On the other hand, the effects of clinda- 
mycin and sulfamethoxazole were comparable if treat- 
ment was introduced prior to or at the time of infection 
(p>0.05), while sulfamethoxazole showed better results 
when initiated 48 h postinfection (p<0.02). 
The absence of lethal events in the survivors from 
all experiments during the 5-week observation period 
following the discontinuation of treatment suggested 
clearance of tachyzoites fiom the host organisms. The 
clearance of tachyzoites was further supported by the 
absence of mortality in animals intraperitoneally sub- 
inoculated with survivor mice brain tissue. On the 
other hand, 100% survival of mice perorally sub- 
inoculated with the same material suggested the 
absence of encysted toxoplasma. No toxoplasma cysts 
were found by examination of native brain tissue 
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Figure 2 Survival in clindamycin-treated mice infected with lo6 RH T gondii tachyzoites according to the time of initiation 
of treatment versus untreated and sulfimethoxazole-treated mice. C=clindamycin; S=sulfimethoxazole; -24=treatment 
initiated 24 h prior to infection; O=treatment initiated at the time of infection; +48=treatment initiated 48 h postinfection. 
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Figure 3 SuMval in clindamycin-treated mice infected with 10’ RH T gondii tachyzoites according to the time of initiation 
of treatment versus untreated and sulfamethoxazole-treated mice. C=clindamycin; S=sulfamethoxazole; -24ztreatment 
initiated 24 h prior to infection; O=treatment initiated at the time of infection; +48=treatment initiated 48 h postinfection. 
preparations. Furthermore, neither tachyzoites nor 
cysts were seen in histologic sections of the brains and 
lungs in any of the animals analyzed, and no signs of 
encephalitis or pneumonia/pneumonitis were observed 
at any time point. In contrast, in sulfamethoxazole- 
treated animals the overall mortahty rate following 
discontinuation of the drug was 46% during the 5 
weeks of observation (data not shown), while histologic 
sections of brain and lung tissue showed evidence of 
both encephalitis and pneumonia. 
DISCUSSION 
The in vivo antitoxoplasma activity of clindamycin has 
been evaluated in a number of animal models. Some 
studies showed protective effects of clindamycin in both 
systemic toxoplasmosis [13,23] and TE [14], while 
others failed to do so [15,16]. These conflicting results 
may be attributed to Merences in parasite strains 
and inoculation routes, drug dosage, and mode and 
duration of treatment. 
The murine model we developed for the evalua- 
tion of drug efficacy showed the protective effect of 
clindamycin administered for 3 weeks at a dose of 400 
mg/kg to be a function of the inoculum size, ranging 
&om 100% survival of animals infected with 10’ RH 
strain parasites to no survivals in animals infected with 
lo6 parasites. The efficacy of clindamycin was also 
initiation time dependent; thus, if clindamycin was 
introduced before or at the time of infection, animals 
infected with lo2 parasites were 100% protected, versus 
58% ifit was introduced 48 h postinfection. The thera- 
peutic potential of clindamycin was further demon- 
strated by increased mean suMval times of animals 
infected with any inoculum size, irrespective of the 
time of initiation of treatment, except in animals 
infected with lo6 parasites if initiated 48 h post- 
infection. The lower efficacy of clindamycin if intro- 
duced 48 h postinfection may be a consequence of its 
delayed mode of action. Fichera et al. 1181 recently 
showed that clindamycin acts by markedly inhibiting 
the replication of toxoplasma within the parasito- 
phorous vacuole of the second generation. Given the 
RH parasite replication rate of one cycle per 6-8 h, 
when treatment is initiated 48 h postinfection the initial 
parasite burden has already risen up to 250-fold. There- 
fore, a later initiation time acts ultimately as an initially 
hlgher parasite burden. However, our results show 
that at an appropriate parasite dosejdrug dose ratio, 
clindamycin can provide complete protection. 
Whether clindamycin can eliminate T gondii, as 
suggested by the absence of biological and histologic 
evidence for the presence of either tachyzoites or cysts 
in the clindamycin-treated survivors in our model, 
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remains to be elucidated by investigations at the mole- 
cular level. 
The toxoplasmacidal capacity of clindamycin in 
acute toxoplasma infection supports the use of clinda- 
mycin in clinical situations involving the prohferative 
stage of the parasite. A limitation, however, to direct 
extrapolation of the data presented may be the dose of 
clindamycin used in our experimental model, which 
surpasses the dose usually administered in human 
therapy by 5-1 0-fold. However, preliminary experi- 
ments involving doses reduced to 50 mg/kg and 25 
mg/kg per day have shown promising results in terms 
of efficacy, and further work is currently underway in 
our laboratory. 
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